CSIMarket
 
Hoth Therapeutics Inc  (NASDAQ: HOTH)
Other Ticker:  
 
 
Price: $1.0700 $-0.01 -0.926%
Day's High: $1.08 Week Perf: -7.76 %
Day's Low: $ 1.01 30 Day Perf: -30.97 %
Volume (M): 268 52 Wk High: $ 3.80
Volume (M$): $ 287 52 Wk Avg: $1.03
Open: $1.03 52 Wk Low: $0.58



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 7
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Hoth Therapeutics Inc
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological conditions. They aim to address unmet medical needs in the field of dermatology using their proprietary technologies. The company's primary focus is on the development of therapeutics for patients suffering from skin diseases such as atopic dermatitis and psoriasis. Hoth Therapeutics Inc utilizes a combination of drug compounds and medical devices to provide potential solutions for these conditions. They are dedicated to improving the quality of life for patients and advancing the field of dermatology.


   Company Address: 1 Rockefeller Plaza New York 10020 NY
   Company Phone Number: 756-2997   Stock Exchange / Ticker: NASDAQ HOTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY   -4.09%    
EBS   -5%    
PRTA   -1.14%    
REGN   -5.03%    
SRPT   -2.11%    
VRTX   -1.44%    
• View Complete Report
   



Stock Offering

Hoth Therapeutics' Exercise of Warrants Raises $4.2 Million, Fueling Innovation in Biopharmaceutical Space

Published Wed, Mar 27 2024 6:00 PM UTC

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
NEW YORK, March 27, 2024 - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, recently made a significant announcement regarding the exercise of certain outstanding warrants. The company has entered into a definitive agreement to immediately exercise these w...

Hoth Therapeutics Inc

Hoth Therapeutics Inc. Reports Impressive Revenue of $5.6 Thousand in Latest Fiscal Period



Hoth Therapeutics Inc, a biopharmaceutical company, has recently experienced a significant downturn in its stock performance and reported mixed financial results. With a sharp decline in stock prices and underwhelming revenues, shareholders and investors may wonder how these developments will impact the company's future prospects.
1. Declining Stock Performance:
During the past five trading days, Hoth Therapeutics Inc's stock plummeted by -9.01%. Furthermore, the year-to-date performance shows a substantial decrease of -83.08%. The stock has reached its 52-week low, indicating a loss in investor confidence. This declines raises concerns about the company's overall stability and future potential.

Hoth Therapeutics Inc

Hoth Therapeutics Inc Unveils Astonishing Revenue Surge of $0.001548 Million, Setting New Industry Benchmark in Fiscal Year Ending June 30th, 2023



Hoth Therapeutics Inc, a major player in the pharmaceutical industry, recently released its financial results for the fiscal time-frame ending June 30, 2023. The company reported a revenue of $0.001548 million, showcasing its ability to generate income, albeit modest. Furthermore, Hoth Therapeutics Inc recorded a net deficit of $-1.873 million during this period, indicating an improvement from the previous year's deficit of $-2.678 million. These figures invite curiosity about the potential impact on the company's future performance and its readiness to tackle upcoming challenges.
Positive Revenue Growth:
Despite the relatively low revenue of $0.001548 million, the fact that Hoth Therapeutics Inc reported any revenue at all is a promising sign. Generating income, even at a modest level, demonstrates that the company has successfully commercialized some of its products. This increases investor confidence and indicates the potential for future revenue growth.

Hoth Therapeutics Inc

Hoth Therapeutics Inc Outperforms Expectations with Narrowing Operating Deficit in Q1 2023

Hoth Therapeutics Inc Reports Operating Deficit for Q1 2023
In a recent announcement, Hoth Therapeutics Inc revealed that it had reported an operating deficit of $-2.192817 million for the first quarter of 2023. While this may not seem like a good sign at first glance, it actually represents a significant improvement over the same quarter in 2022 when the operating deficit was $-2.660694 million.
As one of the overlooked corporations in the Major Pharmaceutical Preparations industry, Hoth Therapeutics' positive results are a good indicator of the company's overall condition. While it is true that growing businesses like Hoth Therapeutics need to develop their revenue sources, it is equally important for them to operate cost-effectively in order to remain competitive in the industry.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com